We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ETX market cap is 52.55M. The company's latest EPS is GBP -0.0191 and P/E is -4.71.
| Year End January 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 456k | 317k | 477k | 475k | 318k |
| Operating Income | -2.89M | -4.49M | -9.57M | -10.24M | -13.79M |
| Net Income | -2.35M | -3.68M | -8.07M | -8.27M | -11.17M |
| Year End January 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 4.79M | 14.31M | 29.76M | 34.64M | 24.97M |
| Total Liabilities | 284k | 427k | 1.79M | 1.6M | 2.98M |
| Total Equity | 4.5M | 13.88M | 27.97M | 33.04M | 21.99M |
| Year End January 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | -2.03M | -3.36M | -7.8M | -8.01M | -10.9M |
| Investing | -1,000 | -5.07M | -9.94M | 15.31M | 232k |
| Financing | -35k | 12.6M | 22.33M | 13.05M | -359k |
| Market Cap | 52.55M |
| Price to Earnings Ratio | -4.71 |
| Price to Sales Ratio | 180 |
| Price to Cash Ratio | 2.54 |
| Price to Book Ratio | 2.39 |
| Dividend Yield | - |
| Shares Outstanding | 583.84M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -15.49% |
| 52 Week High | 18.50 |
| 52 Week Low | 8.00 |
| Spread (Intraday) | 0.5 (5.26%) |
| Company Name | E-therapeutics Plc |
| Address |
4 kingdom street london |
| Website | https://www.etherapeutics.co.uk |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
